Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06819293 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Oversightv3
  2. Eligibility criteria shortened, about 9 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Trial Details
NCT Number NCT06819293
Lead Sponsor Grit Biotechnology
Conditions
(from sponsor)		 Advanced Clear Renal Cell Carcinoma, Adult
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov